Thursday, 5 November 2026European Markets

NICOX Stock Impressive Jump 32% So Far On Friday, Outperforms Market

Loading stream...

(vianews) - shares of nicox (cac 40: cox.pa) jumped by a staggering 32.53% to €0.77 at 11:05 est on friday, following the last session's downward trend. cac 40 is jumping 0.26% to €7,500.04, after four sequential sessions in a row of gains. this seems, at the moment, a somewhat up trend exchanging session today.

nicox's last close was €0.58, 72.06% below its 52-week high of €2.09.

about nicox

nicox s.a. operates as an ophthalmology company in france and internationally. the company develops solutions to maintain vision and improve ocular health. its lead product candidate is ncx 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. the company is also developing ncx 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and ncx 1728.it offers vyzulta, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and zerviate, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. the company was founded in 1996 and is headquartered in valbonne, france.

earnings per share

as for profitability, nicox has a trailing twelve months eps of €-1.26.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -43.38%.

sales growth

nicox's sales growth for the current quarter is 158%.

volume

today's last reported volume for nicox is 834147 which is 719.88% above its average volume of 101739.

volatility

nicox's last week, last month's, and last quarter's current intraday variation average was a negative 0.51%, a negative 2.06%, and a positive 2.51%.

nicox's highest amplitude of average volatility was 1.43% (last week), 3.12% (last month), and 2.51% (last quarter).

yearly top and bottom value

nicox's stock is valued at €0.77 at 11:05 est, way under its 52-week high of €2.09 and way higher than its 52-week low of €0.58.

more news about nicox (cox.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com